* Allelix Biopharmaceuticals Inc., of Ontario, Canada,said clinical evaluation of a fragment of parathyroidhormone (PTH), which is similar to Allelix'sosteoporosis drug, demonstrates PTH can add new bonequickly in people suffering from osteoporosis. Allelix'sdrug, ALX1-11, is a recombinant full-length human PTHbeing tested in Phase II trials involving 240 post-menopausal women with the degenerative bone disease.

* Cytel Corp., of San Diego, received a $3.3 million,four-year grant from the National Institutes of Health(NIH) to develop a peptide-based vaccine for HIV-1. Thefunds were awarded through the NIH's StrategicPrograms for Innovative Research on Aids Treatment.

* Genentech Inc., of South San Francisco, completed thepurchase of 100 acres in Vacaville, Calif., and launchedpreliminary work on a more than $150 million first phasefor construction of a new manufacturing facility,scheduled to be complete by late 1998.

* Geron Corp., of Menlo Park, Calif., received threeresearch grants worth $2.4 million to develop drugs anddiagnostics based on telomerase, which the companydescribed as an "immortalizing enzyme" linked to manycancers. The funding was awarded by the NationalCancer Institute, the California Breast Cancer ResearchProgram and the Small Business Innovation ResearchProgram.

* Immune Response Corp., of Carlsbad, Calif., began aPhase II clinical trial for psoriasis with a drug that thecompany described as synthetic peptides designed toinhibit the activation of T cells believed to be responsiblefor the disease. The study will involve up to 90 patients.

* Ostex International Inc., of Seattle, settled its tradename litigation with Ostech Inc., of New Haven, Conn.,after the latter agreed to change its business title toNorland Medical Systems Inc.

* Perkin-Elmer Corp., of Norwalk, Conn., entered anagreement with the U.K.-based Oxford Molecular Groupplc to develop computer software aimed at acceleratingand broadening the scope of DNA sequencing. Financialterms were not disclosed. Oxford Molecular willcollaborate with Perkin-Elmer's Applied BiosystemsDivision in Foster City, Calif.

* Pharmos Corp., of New York and Alachua, Fla., raised$9 million through the sale of 6 million units, whichconsist of one share of common stock and one warrant topurchase .075 shares at $1.80 per share. The exercise datefor the five-year warrant begins one year after the closeof the placement.

* Protein Design Labs Inc., of Mountain View, Calif.,began a Phase II trial of its human anti-cytomegalovirus(CMV) antibody to prevent CMV infection in bonemarrow transplant patients. The studies at three U.S.medical centers will involve 168 patients.

* Sankyo Co. Ltd., of Tokyo made a $1.5 million equityinvestment in Ligand Pharmaceuticals Inc., of San Diego,through the purchase of 189,274 Ligand shares tocontinue their collaboration targeting anti-inflammatorydrugs based on cell adhesion modulators developed byLigand's subsidiary, Glycomed Inc., of Alameda, Calif.Sankyo and Glycomed entered an alliance in July 1994.

* Transcend Therapeutics Inc., of Cambridge, Mass.,formerly called Free Radical Sciences Inc., received $2million in private financing, bringing the company's totalfunding to $5 million. Transcend's lead product isProcysteine designed to replenish the peptide,glutathione, which protects cells from oxidative damage.The drug initially is being tested for treatment of multipleorgan dysfunction.

* Athena Neurosciences Inc., of South San Francisco,said preliminary results of a second pivotal trial ofDiastat, or diazepam, showed the drug achieved astatistically significant effect in reducing the number ofrecurrent seizures in epileptics suffering from a conditioncalled acute repetitive seizure. The data revealed that 45percent of the patients treated with Diastat experiencedanother seizure within 12 hours compared with 64percent who received a placebo. The trial, which testedadministration of the drug for home use, involved 114patients. Athena said based on results of the Phase III trialand an earlier pivotal study the company plans to file anew drug application with the FDA before the end of1995.

* Cortex Pharmaceuticals Inc., of Irvine, Calif., said itsAmpakines, which are compounds aimed at modulatingthe ampa receptor, have demonstrated in preclinicalstudies with rats that the drugs may have a positive effecton schizophrenia. Ampakines are designed to targetdiseases linked to depressed functioning of theglutamatergic pathways in the brain.

(c) 1997 American Health Consultants. All rights reserved.

No Comments